Gold prices steady ahead of Fed decision; weekly weakness noted
On Friday, RBC Capital Markets reiterated its Outperform rating on ADC Therapeutics (NYSE:ADCT) with a steady price target of $8.00, significantly above the current trading price of $1.48. The firm’s analyst highlighted the importance of the upcoming year for the company’s Zynlonta expansion and potential share re-rating. According to InvestingPro data, ADCT is currently trading near its 52-week low, having declined over 50% in the past six months. Despite Zynlonta’s fourth-quarter sales in 2024 totaling $16.4 million, falling short of the anticipated $18.6 million and consensus estimate of $19.2 million, RBC Capital expressed optimism for the drug’s future. While the sales figures were impacted by competition, InvestingPro analysis reveals an impressive gross profit margin of 91.6%, though the company faces challenges with cash burn. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial analysis through the Pro Research Report.
ADC Therapeutics is focusing on expanding Zynlonta’s clinical utility over the long term, amidst a changing competitive landscape. RBC Capital drew attention to the anticipated update on LOTIS-5 data expected in late 2025, which is seen as a significant catalyst that could enhance Zynlonta’s revenue base. In addition to LOTIS-5, the analyst noted upcoming LOTIS-7 updates expected in the second quarter of 2025 and full data in the second half of the same year. Incremental updates are also anticipated at the American Association for Cancer Research (AACR) meeting in April 2025.
The firm has adjusted its model for ADC Therapeutics following the quarterly updates but chose to maintain its Outperform rating, which includes a Speculative Risk qualifier, along with the $8 price target. The analyst’s commentary underscored the critical nature of the upcoming year for the company, as it seeks to de-risk the expansion of Zynlonta and potentially re-rate its shares.
ADC Therapeutics is at a pivotal point, with significant updates on the horizon that could shape the trajectory of Zynlonta’s market success. The company’s strategy to navigate the competitive landscape and broaden the drug’s clinical applications will be closely watched by investors and industry stakeholders alike. With a current ratio of 3.82, InvestingPro data shows the company maintains strong liquidity to fund its development programs, though analysts don’t expect profitability this year. Discover detailed valuation metrics and growth potential through InvestingPro’s comprehensive research tools.
In other recent news, ADC Therapeutics reported its Q4 2024 earnings, revealing a mixed financial outcome. The company exceeded expectations with an earnings per share (EPS) of -$0.25, surpassing the anticipated -$0.43. However, revenue fell short, reaching $16.91 million compared to the forecasted $18.85 million. Despite the revenue miss, ADC Therapeutics managed to significantly reduce its net loss from $240.1 million in 2023 to $157.8 million in 2024.
The company ended the year with $251 million in cash and cash equivalents, projecting a positive cash runway into the second half of 2026. In terms of market strategy, ADC Therapeutics continues to focus on expanding the presence of ZENLANTA, particularly in the DLBCL and indolent lymphoma markets. Additionally, promising trial results have been reported in DLBCL and indolent lymphomas, with further data catalysts expected in 2025.
Furthermore, ADC Therapeutics is actively pursuing research collaborations to advance its early-stage solid tumor pipeline. The company maintains a positive outlook, with ambitious revenue forecasts for future quarters and years, as highlighted by CEO Amit Malek’s emphasis on the potential of the LOTUS5 trial to significantly boost ZENLANTA’s market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.